Neuberger Berman Group LLC Viking Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $3.52 Million - $4.98 Million	-70,669 Closed	0 $0
Q2 2024 Nov 14, 2024	BUY	$47.39 - $80.2 $196,005 - $331,707	4,136 Added 6.22%	70,669 $3.75 Million
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $196,005 - $331,707	4,136 Added 6.22%	70,669 $3.75 Million
Q1 2024 Nov 14, 2024	SELL	$17.4 - $94.5 $695,408 - $3.78 Million	-39,966 Reduced 37.53%	66,533 $5.46 Million
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $1.16 Million - $6.29 Million	66,533 New	66,533 $5.46 Million
Q4 2023 Nov 14, 2024	BUY	$9.24 - $19.64 $331,069 - $703,701	35,830 Added 50.7%	106,499 $1.98 Million
Q4 2023 Feb 09, 2024	BUY	$9.24 - $19.64 $205,017 - $435,772	22,188 Added 26.32%	106,499 $1.98 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $16,270 - $23,840	1,490 Added 1.8%	84,311 $933,000
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $1.23 Million - $2.05 Million	82,821 New	82,821 $1.34 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.